A phase 3 clinical trial to evaluate long-term immunogenicity and boostability of Purified Chick-Embryo Cell Rabies Vaccine in adults following primary series of pre/exposure prophylaxis.

Trial Identifier: 205214
Sponsor: GlaxoSmithKline
Start Date: October 2015
Primary Completion Date: December 2022
Study Completion Date: December 2022
Condition: Rabies Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Austria Wien, Austria, 1090
Germany, Bayern Muenchen, Bayern, Germany, 80802
Germany, Berlin Berlin, Germany, 13353
Germany, Berlin Berlin, Germany, 10117
Germany, Hamburg Hamburg, Germany, 20359
Germany, Mecklenburg-Vorpommern Rostock, Mecklenburg-Vorpommern, Germany, 18057
Switzerland Zuerich, Switzerland, 8001